D
ecades of research have yielded methods for cancer treatment that can be more specifically tailored to a patient's cancer than broader strategies such as radiotherapy or chemotherapy. However, these methods -which include immunotherapy and therapies targeted at cancercausing genes -are dogged by the problem of acquired resistance, in which many patients initially respond to the treatment but subsequently become unresponsive and experience relapse. Resistance is commonly thought to arise from the proliferation of a small proportion of resistant cells in a mixed tumourcell population. But on page 412 of this issue, Landsberg et al. 1 show, using a mouse model of melanoma, that resistance to a promising form of immunotherapy can develop when cancer cells change their protein-expression profile in response to treatment*.
Cancer immunotherapies are designed to initiate or boost a person's immune response to a tumour. One way of doing this is by adoptive cell transfer (ACT), in which patients receive transfusions of immune cells called T cells that target cancer-specific antigens (an antigen is a substance that elicits responses from *This article and the paper under discussion 1 were published online on 10 October 2012.
about the mechanisms underlying acquired resistance in patients receiving ACT. However, there is generally a high initial response rate to ACT, so understanding what then happens to lead to resistance is a challenge worthy of investigation.
The most common sources of tumourantigen-specific cells for ACT are tumourinfiltrating lymphocytes (TILs) or blood T cells that are isolated from the patient and modified before being reintroduced. In the case of TILs, which already have tumour specificity, this involves expanding the cell population and activating the cells. In therapies using blood T cells, which are initially not tumour specific, the cells' antigen receptors are first genetically engineered to recognize tumour antigens 2 . Tumour responses tend to last longer in TILbased ACT, probably because each TIL preparation might target several tumour antigens simultaneously 3 . However, TILs can be isolated from only a limited number of patients with melanoma, which hinders the application of this approach. Genetically engineered T cells address this problem, because every patient has ample numbers of nonspecific T cells that can be harvested for this purpose. But although ACT based on genetically modified T cells results in a high frequency of positive initial responses, relapse often occurs a few months after the start of treatment [4] [5] [6] . To study how this resistance arises, Landsberg et al. developed a mouse model of melanoma and an ACT protocol (using genetically modified T cells) that recapitulates the clinical course seen in people. The widely accepted view of how resistance to ACT therapy arises is that tumours contain small numbers of cells (called subclones) with genetic variations that give them a proliferative advantage in the face of the immune-cell attack. However, Landsberg and colleagues observed that the inflammatory response initiated by ACT caused a proportion of the melanoma cells to lose some of the antigens that defined the cells as being cancerous -a change that the authors describe as 'dedifferentiation' (Fig. 1) . This is the key to their new hypothesis for tumour resistance: the T cells transferred in ACT are designed to target tumour-specific antigens, but precisely these antigens are lost by the tumour cells during treatment. The authors also identify the pro-inflammatory cell-signalling molecule tumour necrosis factor-α (TNF-α) as a crucial mediator of this cellular change, and show that the change is reversible, meaning that the cancer cells can reacquire expression of the antigens when the treatment is stopped and the inflammation resolves.
Although the cellular dedifferentiation described by Landsberg and colleagues is a new concept in cancer resistance, the idea fits well with previously proposed mechanisms of resistance to tumour-antigen-specific immunotherapy. For example, resistance has been observed after increased proliferation of subclones that did not express a tumour antigen that was being targeted by ACT, and also as a result of some or all cells in a tumour lacking key proteins in the cellular pathway by which antigens are 'presented' to T cells 7 . However, resistance to immunotherapy may also arise from changes in the transferred immune cells, rather than changes to the characteristics or relative abundance of cancer cells. For example, therapeutic T cells may lose their anti-tumour functions over time in vivo, owing to intrinsic changes in the T cells that shift their activity from cytotoxicity to an immune-tolerant state 8 
